FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Late clinical · capacity Has started a Phase 3 trial to widen the indications of its lead product Latuda.

  • Approval of a Phase 3 trial of Latuda as adjunctive treatment for major depressive disorder. Source

Roles often seen at this stageClinical & PV · Sales & marketing · Regulatory affairs

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Bukwang Pharmaceutical

A pharmaceutical company selling prescription drugs centred on the central nervous system, including Latuda for schizophrenia and bipolar disorder.

Latuda (lurasidone)

Marketed

Schizophrenia and bipolar-disorder drug that reached sixth place in its Korean prescription market two years after launch.

Lurasidone (adjunctive major depressive disorder)

Phase 3

Korean Phase 3 trial to add adjunctive treatment of major depressive disorder as an indication.

Announced

Received approval for a Phase 3 trial of Latuda as adjunctive treatment for major depressive disorder.

Official role guide

Bukwang Pharmaceutical careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 부광약품, '라투다' 우울장애 적응증 추가 임상 돌입 ↗머니투데이 · Published 2026-06-04 · Sources checked 2026-11-15 · Original unavailable
  2. 부광약품 '라투다' 출시 2년만 처방 시장 6위 안착 ↗약사공론 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable